Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE: Emapalumab for IFN-γ–driven sepsis
2024-515255-38-00Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of emapalumab in sepsis, sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: SOFA score improvement at end of treatment. Started Mar 2025; status: completed.
02
Drugs
emapalumab
03
Conditions
sepsis
Beyond the preview
Go deeper on 2024-515255-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515255-38-00.